VIC
VIC supports rapid-pace, high-impact research initiatives that are in the process of safely transitioning from the research lab to patients. It aims to accelerate discovery and development of new products addressing unmet clinical needs, focusing on modulating the immune system for therapeutic benefit in cancer, infectious, and immune-mediated diseases. VIC collaborates with academic and industry scientists worldwide, developing products like biologic immunotherapies, vaccines, microencapsulants, and immune cell therapies.
Industries
Nr. of Employees
small (1-50)
VIC
149 13th Street, 5th Floor, Charlestown Navy Yard, MA 02129-2020
Products
Biologic immunotherapy candidates for cancer
Novel biologic immunotherapy candidates under preclinical and early clinical development intended for specific cancer indications.
Vaccine candidate for HPV-associated cancers
A prophylactic or therapeutic vaccine candidate targeting human papillomavirus–related malignancies, advanced through preclinical development.
Microencapsulation platform for allogeneic transplantation
Microencapsulant technology designed to enable allogeneic cell or tissue transplantation with local immune protection to reduce or avoid systemic immunosuppression.
Allogeneic B cell–based therapy for neurodegenerative injury
Cell therapy product concept using donor B cell infusions intended to modulate inflammation and provide neuroprotective effects in conditions such as ALS and intracranial hemorrhage.
Handheld near-infrared laser adjuvant device
A small, lower-cost near-infrared laser device developed for use as a physical adjuvant to enhance intradermal vaccine responses with reduced sensitivity to skin pigmentation.
mRNA nanoparticle therapeutic strategies
Preclinical approaches combining mRNA nanoparticle delivery with immune checkpoint modulation to restore tumor suppressor function and enhance antitumor immunity.
Biologic immunotherapy candidates for cancer
Novel biologic immunotherapy candidates under preclinical and early clinical development intended for specific cancer indications.
Vaccine candidate for HPV-associated cancers
A prophylactic or therapeutic vaccine candidate targeting human papillomavirus–related malignancies, advanced through preclinical development.
Microencapsulation platform for allogeneic transplantation
Microencapsulant technology designed to enable allogeneic cell or tissue transplantation with local immune protection to reduce or avoid systemic immunosuppression.
Allogeneic B cell–based therapy for neurodegenerative injury
Cell therapy product concept using donor B cell infusions intended to modulate inflammation and provide neuroprotective effects in conditions such as ALS and intracranial hemorrhage.
Handheld near-infrared laser adjuvant device
A small, lower-cost near-infrared laser device developed for use as a physical adjuvant to enhance intradermal vaccine responses with reduced sensitivity to skin pigmentation.
mRNA nanoparticle therapeutic strategies
Preclinical approaches combining mRNA nanoparticle delivery with immune checkpoint modulation to restore tumor suppressor function and enhance antitumor immunity.
Services
Programmatic support and project management to move candidate vaccines and immunotherapies from laboratory discovery through preclinical studies into first-in-human testing and partner handoff.
Collaborative laboratory research programs including preclinical efficacy testing, immune profiling, and platform engineering for vaccines, cell therapies, and delivery systems.
Programmatic support and project management to move candidate vaccines and immunotherapies from laboratory discovery through preclinical studies into first-in-human testing and partner handoff.
Collaborative laboratory research programs including preclinical efficacy testing, immune profiling, and platform engineering for vaccines, cell therapies, and delivery systems.
Expertise Areas
- Vaccine development and clinical translation
- Immunotherapy and cell therapy development
- High-dimensional immunology and immune profiling
- RNA delivery and nanomedicine
Key Technologies
- mRNA nanoparticle delivery
- Extracellular vesicle (EV)-based RNA delivery
- Allogeneic B cell therapy
- Near-infrared laser adjuvant devices
News & Updates
Cancer Moonshot Summit at VIC
VIC hosted a summit to discuss the Cancer Moonshot initiative, focusing on research, access to healthcare, and funding for early-stage scientists.
UKraine & Heal Ukraine Group
Harvard University Medical Scholars-at-Risk program and efforts to train Ukrainian doctors amid ongoing conflict.
Boston’s Burn Doctors Help Save Suffering Ukrainian Children
VIC contributed to medical aid for Ukrainian children with severe burns fleeing the war.
VIC Researchers Present at International Conferences
VIC scientists presented research on antimicrobial blue light, B cell therapy, and cancer vaccines at global forums.
A statement from Nobel laureates supporting Ukraine and condemning Russian aggression.
Analysis of the challenges in developing a coronavirus vaccine due to short-lived natural immunity.
Cancer Moonshot Summit at VIC
VIC hosted a summit to discuss the Cancer Moonshot initiative, focusing on research, access to healthcare, and funding for early-stage scientists.
UKraine & Heal Ukraine Group
Harvard University Medical Scholars-at-Risk program and efforts to train Ukrainian doctors amid ongoing conflict.
Boston’s Burn Doctors Help Save Suffering Ukrainian Children
VIC contributed to medical aid for Ukrainian children with severe burns fleeing the war.
VIC Researchers Present at International Conferences
VIC scientists presented research on antimicrobial blue light, B cell therapy, and cancer vaccines at global forums.
A statement from Nobel laureates supporting Ukraine and condemning Russian aggression.
Analysis of the challenges in developing a coronavirus vaccine due to short-lived natural immunity.